A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity
Latest Information Update: 31 Oct 2024
At a glance
- Drugs SIL-1002 (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions
- Acronyms RAISE
- Sponsors Saol Therapeutics
Most Recent Events
- 30 Oct 2024 According to a Saol Therapeutics media release, data from this study were presented at the Spasticity X Symposium in Houston, Texas.
- 30 Oct 2024 Results presented in a Saol Therapeutics Media Release.
- 19 Sep 2023 According to a Saol Therapeutics media release, topline data from the RAISE Limb Spasticity Trial expected in the second quarter of 2024.